Working arrangement for the collaboration and exchange of information on therapeutic products and medicinal products between DG SANTE/EMA and the New Zealand Ministry of Health

Submitted by Anonymous (not verified) on 8 July 2026 - 9:48

Working arrangement for the collaboration and exchange of information on therapeutic products and medicinal products between DG SANTE/EMA and the New Zealand Ministry of Health

Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive

Submitted by Anonymous (not verified) on 8 July 2026 - 9:24

Orphan designation: allogeneic human induced pluripotent stem cell-derived photoreceptor precursor cells Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype, 20/05/2026 Positive

Orphan designation: (S)-N-(2-(2-Cyclopropylpyridin-4-yl)-4,5,6,7-tetrahydrobenzo[d]oxazol-4-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide Treatment of KCNT1-related epilepsy, 20/05/2026 Positive

Submitted by Anonymous (not verified) on 8 July 2026 - 9:24

Orphan designation: (S)-N-(2-(2-Cyclopropylpyridin-4-yl)-4,5,6,7-tetrahydrobenzo[d]oxazol-4-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide Treatment of KCNT1-related epilepsy, 20/05/2026 Positive

Orphan designation: antisense oligonucleotide against USH2A pre-mRNA Treatment of inherited retinal disease due to dysfunction in the USH2A gene, 20/05/2026 Positive

Submitted by Anonymous (not verified) on 8 July 2026 - 9:24

Orphan designation: antisense oligonucleotide against USH2A pre-mRNA Treatment of inherited retinal disease due to dysfunction in the USH2A gene, 20/05/2026 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More